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ABSTRACT 
Objective: This study was designed to study the release efficacy and glucose tolerance of 14-deoxy, 11, 12-didehydroandrographolide loaded 
polycaprolactone nanoparticles in streptozotocin-nicotinamide induced type 2 diabetes. 
Methods: Biodegradable polymer based novel drug delivery systems had brought a considerable attention to improve therapeutic efficacy and 
bioavailability of various drugs. In this study, 14-deoxy-11, 12-didehydroandrographolide (sparingly water soluble) loaded polycaprolactone (nano-
DDA) was synthesized using polyvinyl alcohol and tween20 as surfactants. MTT assay was performed to analyse the cytotoxicity of both the 
formulations on L6 myoblasts. Free DDA and nano-DDA were administered orally to the streptozotocin-nicotinamide induced experimental diabetic 
rats for 45d. Oral glucose tolerance test (OGTT) was carried out at the end of the study. After one week washout period, animals were administered 
with free and nano-DDA and release efficacy of DDA from polymer matrix and concentration of glucose were analysed. 
Results: MTT assay revealed that nano-DDA prepared using tween-20 as a surfactant elicited cytotoxicity towards L6 myoblasts, whereas nano-
DDA prepared using polyvinyl alcohol as a surfactant remained non-toxic till 10µM. OGTT studies revealed an initial increase of glucose at 30 min 
followed by a progressive decrease in the glucose level. In rat plasma, a gradual decrease in glucose level was observed up to 32h (139 mg/dl) for 
free DDA, whereas nano-DDA exhibited a major decrease in glucose concentration at 32h (115 mg/dl) which continued even after 48h (117 mg/dl).  
Conclusion: A slow and sustained release of DDA from the polymer matrix substantiated that nanoencapsulation enhanced the oral bioavailability 
of DDA which resulted in decreasing the concentration of glucose which could be due to the pronounced antihyperglycemic activity of nano-DDA 
over free DDA. 
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Diabetes mellitus(DM) is a metabolic condition characterized by 
impaired glucose tolerance due to the dysfunction of pancreatic β 
cells or increased resistance to insulin action in the peripheral 
tissues (mainly skeletal muscle and adipose tissue) [1, 2]. The 
alarming rate of worldwide incidence of Diabetes Mellitus 
constitutes a global health issue. As reported by International 
Diabetes Federation (IDF) in 2015, about 415 million people were 
diagnosed with DM and is projected at 642 million by 2040with an 
average increasing case of 3 people every second [3]. 
Among the two types of diabetes, Type II Diabetes Mellitus is the most 
commonly diagnosed form of diabetes found among 90-95% of the 
diabetic population [4], characterized by insulin resistance(IR), which 
is a hallmark of type 2 diabetes. Impaired insulin secretion and insulin 
resistance leads to the dysregulation of glucose homeostasis. 
According to patient’s perspective, oral administration of the drug is 
absolutely not painful and omits uncomfortable interventions. 
However, the oral bioavailability of bioactive compounds is limited 
by the protease enzymes in the gastrointestinal tract and 
hydrophobicity of the bioactive compounds [5]. In the food and 
pharmaceutical industries, the controlled release systems have 
emerged extensively to release the active substances Eg: drugs and 
nutrients [6]. The advancement in material science and 
nanoengineering are being prioritized for encapsulating therapeutic 
agents into a nanoformulation for targeted drug delivery [7, 8].  
The pharmacological potential of bioactive compounds enormously 
depends on their solubility in water [9]. Unfortunately, the sparing 
solubility in water limits their bioavailability and clinical application. 
Hence site-specific or targeted drug delivery, reduction of systemic 
toxicity, improvement of physicochemical property, protection from 
biochemical degradation and improvement of environmental 
stability are the major challenges for designing an ideal delivery 
system [2]. Recently, polymer-based drug delivery systems ventured 
many avenues for increasing efficacy and specific targeting of new, 
as well as already existing drugs. In this perspective, the 
biodegradable polymers are of prime interest due to their advantage 
of elimination of polymer metabolites out of the body by innate 
metabolic processes [10]. 
14-deoxy-11, 12-didehydroandrographolide (DDA) used in the 
present study is a diterpenoid of the annual herbaceous plant 
Andrographis paniculata (Family: Acanthaceae) which have been 
used for many ailments in India as well as in many Asian countries 
[11]. The limited availability of pharmacokinetic data of DDA 
resulted in the delay of further drug development and clinical uses. 
In our previous study, the enhanced bioavailability of nano-
encapsulated DDA in experimental diabetic rats was reported [12]. 
In this present study, nano-DDA was formulated with two types of 
surfactants and their cell viability was analysed and the aim is to 
study the augmented glucose tolerance and release efficacy of the 
nanoencapsulated DDA (nano-DDA). 
MATERIALS AND METHODS 
Chemicals and reagents 
Streptozotocin, Nicotinamide, Metformin, Polyvinyl alcohol and Tween 
20 were procured from Himedia, Mumbai. Polycaprolactone was 
purchased from Sigma-Aldrich limited, Bangalore. 14-deoxy, 11, 12-
didehydro andrographolide was purchased from Apeksha Research 
centre private limited, Indore, Madhya Pradesh, India. 
Cell culture 
Dulbecco’s modified eagle’s medium (DMEM) supplemented with 
10% Fetal bovine serum (FBS) was used to culture L6 myoblasts (rat 
skeletal muscle cells) with streptomycin (75 µg/ml), penicillin (120 
units/ml), amphotericin B (3 µg/ml) and gentamycin (160 µg/ml) in 
5% CO2. 
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Formulation and characterization of nanoencapsulated DDA 
Four formulations were attempted by varying the drug to polymer 
ratio, type of surfactant and sonication time. Polycaprolactone (PCL) 
was used as a biodegradable polymer. The nanoparticles containing 
PCL-DDA conjugate and free PCL were fabricated by solvent 
evaporation technique [13]. Briefly, known amounts of the DDA and 
PCL were added to 0.5 ml of dichloromethane, stirred to ensure that 
the materials were dissolved. The organic phase was introduced 
slowly into either 0.5% PVA or 1% Tween 20 solution resulting in an 
emulsion. Bandelin sonopuls sonicator (model UW2070, BANDELIN 
electronic GmbH and Co. KG, Berlin) was used to break down the 
resulting emulsion into nanodroplets. The solvent was evaporated 
with constant stirring using magnetic stirrer at 60 rpm for 4 h to form 
a colloidal suspension of nano-DDA. The nanoparticles were collected 
as a precipitate by centrifugation at 14000 rpm for 15 min. The pellet 
was air-dried and then stored at 4 °C. Empty PCL nanoparticles were 
prepared without the drug using the same methodology. 
Assessment of cytotoxicity by MTT assay 
The cytotoxic effect of nanoencapsulated drug prepared with 
polyvinyl alcohol (PVA) and tween 20 as surfactants was 
Measurement of release efficacy 
analysed 
by MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium 
bromide) assay. The MTT assay is a colorimetric assay for evaluating 
cell viability. NAD(P)H-dependent cellular oxidoreductase enzyme 
reduces the yellow tetrazolium dye (MTT) to insoluble formazan 
crystals (purple colour). These enzymes are present largely in the 
cytosolic compartment of the cell. A solubilization solution was 
added to dissolve the insoluble product. The absorbance was 
read at570 nm by a UV spectrophotometer [12-16].  
% Cell viability =
O. D. of test
 O. D. of control
× 100 
After one week washout period, experimental animals were 
administered with free DDA (50 mg/kg b.w.) and nano-DDA (50 mg 
of nanoparticle-containing 9.4 mg DDA/kg b.w.) 
The area under the curve (AUC) was calculated using the trapezoidal 
method. The release efficacy of DDA from polymer matrix 
formulation was extrapolated using the AUC. Release efficacy 
percentage was calculated using the following formula [17]: 




Where AUC is the area under the curve of drug release chromatogram 
and AUCs
Experimental animals and diet 
 is the area under the curve of the standard sample. 
Healthy adult male Wistar rats (150-200g) were used for the study. 
Rats were housed in polypropylene cages lined with husk in standard 
environmental conditions (temperature 25±2 °C with dark/light cycle 
12/12h; 55±10% humidity). Priorly the experimental protocol was 
subjected to the Institutional Animal Ethical Committee and was 
approved by the same before beginning the experiment 
(53/IAEC/2011). Animals were fed with standard pellet diet and 
water ad libitum. 
Experimental induction of diabetes 
Streptozotocin (STZ) and nicotinamide (NIC) were dissolved in freshly 
prepared 0.1M citrate buffer (pH 4.5) and in normal physiological 
saline respectively and stored on ice prior to use. A single injection of 
Streptozotocin (45 mg/kg body weight), 15 min after the 
administration of nicotinamide (110 mg/kg body weight) was given 
intraperitoneally to induce Diabetes mellitus in overnight fasted rats. 
Hyperglycemia was confirmed by the raised blood glucose levels, 
determined on 3rdd and then on 7thd after induction. The rats with 
blood glucose levels above 250 mg/dl were used for the study [18]. 
Experimental design and treatment of animals 
Experimental design of free DDA 
The rats were divided into seven groups comprising of five rats in 
each group. All rats except control and the diabetic group were 
administered with the drug (orally) for 45 d. 
Group I-Control rats received Carboxymethylcellulose (0.5%) 
Group II–Control rats administered orally with DDA (50 mg/kg body 
weight) 
Group III–Diabetic rats  
Group IV–Diabetic rats administered orally with DDA (10 mg/kg 
body weight) 
Group V–Diabetic rats administered orally with DDA (25 mg/kg 
body weight) 
Group VI–Diabetic rats administered orally with DDA (50 mg/kg 
body weight) 
Group VII–Diabetic rats administered orally with Metformin (500 
mg/kg body weight) 
Experimental design for nano-DDA 
Group I-Control rats received Carboxymethylcellulose  
Group II–Control rats administered with nano-DDA (50 mg/kg b.w.) 
Group III–Diabetic control rats (NIC+STZ induced) 
Group IV–Diabetic rats administered with DDA (50 mg/kg b.w.) 
Group V–Diabetic rats administered with nano-DDA (25 mg/kg b.w.) 
Group VI–Diabetic rats administered with nano-DDA (50 mg/kg b.w.) 
Group VII–Diabetic rats administered with Metformin (500 mg/kg b.w.) 
Animals were administered with DDA for 45 d (1 ml/rat) in 0.5% 
carboxymethyl cellulose as a vehicle. DDA and Metformin were 
suspended in 0.5% CMC prepared in autoclaved distilled water prior 
to oral administration to experimental animals. 
Oral glucose tolerance test (OGTT) 
After treatment for 45 d with free and nano-DDA, glucose tolerance 
test was performed on overnight fasted rats [19]. Animals of all 
groups were administered with glucose (2g/kg) orally. Group IV, V, 
VI were treated orally with drug and group VII was administered 
with metformin (500 mg/kg), 30 min prior to oral glucose 
administration. The blood samples were withdrawn through retro-
orbital plexus at 30, 60, 90 and 120 min after glucose administration. 
Concentration of glucose 
Blood samples were collected from retero orbitol plexus of the rats 
at predetermined time intervals and plasma was separated 
immediately by centrifuging of heparinized blood at 3500 rpm for 
10 min. The concentration of glucose in plasma samples was 
estimated using Robonik prietest GOD-POD glucose estimation kit, 
Robonik (India) Private limited, Mumbai, India. 
Statistical analysis 
Results were expressed as mean±SD. The data were analysed using 
Graphpad Prism 5.03 statistical software (Graphad software Inc., La 
Jolla, CA). The statistical significance was evaluated by oneway 
analysis of variance (ANOVA) and Dunnet’s multiple comparison 
tests was performed to determine significant differences between 
groups. The criteria for statistical significance were P<0.05. 
RESULTS AND DISCUSSION 
Cell viability assay 
The capability of cells in reducing MTT delivers an indication of 
mitochondrial integrity and activity, which could be inferred as a 
measure of viability of cell [20]. The results of the cell viability study 
were presented in the form of percentage viability remains after 
treatment with PVA and Tween 20 formulations (fig. 1). The results 
revealed that the nano-DDA (Tween20) treated cells, exhibited a 
significant, (P<0.05) decrease in cell viability on the L6 myoblasts. 
The percentage viability of L6 cells after treatment with the 
aforementioned formulation was found to be 67% in 1nM. A major 
decline in the cell viability was noticed at 10µM (34%). But the cells 
treated with nano-DDA (PVA) did not display any change in cell 
Sujatha et al. 
Int J App Pharm, Vol 9, Issue 6, 2017, 51-53 
 
51 
viability (98% viable on par with the control). In addition, nano-DDA 
(PVA) incubated L6 myoblasts did not elicit cytotoxicity to L6 
myoblasts up to 10µM. This is suggestive of the compatibility of 
nano-DDA (PVA) with a living system. Hence nano-DDA with PVA as 
the surfactant has been used in further experimental procedures, 
omitting nano-DDA with tween20 as surfactant since it elicited a 
decline in cell viability. ChibuezeIhekwereme (2014) reported that 
calu-3 cells (bronchial adenocarcinoma of the airway) incubated 
with 0.2% Tween 20 for 60 min exhibited cytotoxicity with 
57.1%±8.1% viability of the cells [21]. Atefeh Hekmat et al. (2016) 
stated that Docetaxel-Loaded Nanomicelles using Tween 20 as a 
surfactant resulted in a higher C26 cell death rate [22]. Vimala et al. 
(2011) reported that usually at the end of the preparation of 
nanoencapsulation, the surfactant used was removed by centrifuging 
the nanoparticles. But the surfactant which adsorbed on the surface 
of the nanoparticles could not be removed completely due to the 
formation of the interconnected network formed on the surface [23]. 
According to Sahoo et al. (2002) up to 13% of surfactant level is 
permissible which could influence the physical and biological 
properties of the nanoformulation [24]. 
 
 
Fig. 1: Cell viability of nano-DDA (PVA) and nano-DDA (Tween-20) using MTT assay. The values are mean±SD, (*) p<0.05 as compared 
with control, sol. control-Solvent control 
 
Release efficacy percentage (%) 
The in vitro release of DDA loaded nanoparticles appeared to be two-
stage processes. Initially there was a burst release of DDA from 
polymer matrix was observed. After that release of DDA was at 
constant rate. Generally, drug release from the polymer matrix 
depends on the diffusion of the drug, the erosion and the swelling of 
the polymer matrix and degradation of polymer [25]. The release 
efficacy of DDA from nanoparticulate matrix is tabulated (table 1). 
Release of DDA from nano DDA (DDA loaded PCL nanoparticles) 
occurred in a controlled manner. When the nanoparticles were 
exposed to the aqueous environment, the initial burst release which 
was less than 20% that lasted up to 4h. Later, a gradual and sustained 
release of drug from the nanoparticulate matrix, which increased up to 
74% in 16h followed by a fall in release efficacy, was observed. At 48 h 
about 4% of DDA release was observed. The slower and sustained 
release of DDA may possibly be endorsed the diffusion of the DDA 
loaded within the core of the nanoparticle matrix. You ling et al. (2008) 
reported that paclitaxel loaded PLGA nanoparticles exhibited a two-
staged release mode from the nanoparticle [25]. 
 
Table 1: Release efficacy of DDA from PCL polymer matrix 
Time (h) AUC (nano-DDA) (ng) Release efficacy (%) 
0.5  0 0 
1  15.59±0.72 1.20±0.03 
2 91.76±2.45 7.094±.96 
4 253.41±4.67 19.59±.75 
8 572.02±3.67 44.22±2.49 
16 961.72±4.89 74.35±2.96 
24 499.66±3.26 38.63±2.56 
32 182.16±2.95 14.083±0.83 
48 54.82±2.56 4.23±0.025 
The values are expressed as mean±SD, n=3 consecutive experiments, AUC-area under curve 
 
Oral glucose tolerance test 
The effect of DDA on reducing the plasma glucose level in glucose 
loaded (2g/kg) rats was displayed in fig. 2. Initially, there was a sharp 
elevation in 30 min after glucose loading in all groups. DDA treated 
rats displayed a dose-dependent decline in the glucose level from 60 to 
120 min similar to the control rats. However, the restoration from 
hyperglycemia was not observed even at 120 min in the diabetic rats, 
which differs significantly (P<0.05) with control rats, in which the 
glucose level gradually reverted back to the normal level after 30 min. 
The results from the observation clearly indicated that the increment 
in the blood glucose found in the oral glucose tolerance turned into 
significantly greater in diabetic rats than the treatment groups. 
Zhaoxia Liu et al. (2013) reported that compared to diabetic control, 
DTH extract treated group showed significant hypoglycaemia and 
steady decline which exhibited a similar effect to metformin on OGTT 
[26]. Gerardo et al. (2000) reported that insulin-loaded PLGA 
formulation did not show any increase in blood glucose levels even at 
800 mg/kg subcutaneous load of glucose to rats, which substantiated 
that the formulation is bioactive and useful in controlling elevated 
blood glucose levels [27]. Lei song et al. (2014), stated that the blood 
glucose was found to be effectively lowered in overnight fasted 
diabetic animals administered with nanoencapsulated insulin–
chitosan complexes [28]. 
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Fig. 2: Effect of free and nano-DDA on Oral glucose tolerance test in streptozotocin-nicotinamide-induced diabetic rats. Data represented 
as mean±SD, n=5.*p<0.05 as compared with diabetic group, #p<0.05 as compared with control, dia-diabetic 
 
Concentration of glucose 
The blood plasma profile of the rats after oral administration of free 
and nano-DDA was analysed. As displayed in table 2, the plasma of 
free DDA treated rats exhibited a dose-dependent decrease in 
glucose concentration. A major decrease in glucose level (115 
mg/dl) was observed at 2h in which the Tmax for free DDA as 
reported by Nagalakshmi et al.(2017) [12]. There was a gradual 
decrease in glucose level was observed which lasted up to 32h. At 48 
h, an elevation in the glucose level was observed which could be due 
to the lesser concentration of DDA in plasma. On the other hand, the 
nano-DDA treated rats showed a dose dependant decrease in the 
glucose concentration and a major decrease in the glucose level (102 
mg/dl) at 16h, which was the Tmax 
 
Table 2: Glucose concentration (mg/dl) at various time points after oral administration of nano-DDA (PVA) formulation to diabetic rats 
for nano-DDA as reported in our 
previous studies. In contrast to free DDA, nano-DDA maintained a 
declined glucose level of 117 mg/dl even at 48 h, which was about 
189 mg/dl in free DDA treated rats at 48h. As reported by Zadeh et 
al. (2017), nanoencapsulation of insulin using PVA as a surfactant 
enhanced the absorption of insulin via the intranasal route of 
delivery [17]. Seema et al. (2017) reported that upon administration 
of repaglinide loaded microspheres to experimental diabetic rats, a 
glucose level of the formulation started to decrease significantly 
after 1 h which continued up to the eighth h indicating controlled 
release of drug from the formulations [29]. 
Time(h) free DDA nano-DDA 
0.5 143±2.4 125±2.78 
1 137±1.5 122±3.67 
2 115±1.37 118±2.89 
4 121±1.37 112±2.65 
8 126±2.65 109±2.82 
16 129±2.33 102±3.98 
24 131±2.9 109±2.95 
32 139±2.48 115±3.1 
48 189±3 117±2.7 
Data represented as mean±SD, n=5, PVA-polyvinyl alcohol 
 
CONCLUSION 
The oral administration of nanoencapsulated DDA exhibited an 
enhanced oral bioavailability of DDA than free DDA, by reducing the 
first-pass metabolism of DDA. However, further studies using clinical 
trials may confirm the results obtained in this study. Henceforth, the 
nano-DDA can be considered as a potential therapeutic candidate in 
the antidiabetic drug. This work opens a door for discovery of novel 
potential antihyperglycemic agents. 
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